50
Participants
Start Date
May 1, 2014
Primary Completion Date
November 20, 2019
Study Completion Date
May 5, 2021
Peptide Vaccine (LPV7) + Tetanus peptide
1.5 mL administered half intradermally and half subcutaneously.
PolyICLC
1 mL administered half intradermally and half subcutaneously
Resiquimod
500 mg applied to vaccine site after vaccine administration
IFA
2 mL administered half intradermally and half subcutaneously
University of Virginia, Charlottesville
MDAnderson Cancer Center, Houston
University of Virginia
OTHER
Craig L Slingluff, Jr
OTHER